Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

Share Price is delayed by 15 minutes
Get Live Data
50.55    0.00 (0.00%)
Bid:
49.60
Ask:
51.50
Spread: 1.90 (3.831%)
Market Cap: £193.32m
BSC Live PriceLast checked at - London Stock Exchange

Intraday Br.small Co.2 Share Chart

Interim Management Statement

19 May 2009 13:36

RNS Number : 5073S
British SmallerTechCompaniesVCT2PLC
19 May 2009
 



BRITISH SMALLER TECHNOLOGY COMPANIES VCT 2 PLC ("the Company")

INTERIM MANAGEMENT STATEMENT

For the quarter ended 31 March 2009

British Smaller Technology Companies VCT 2 plc presents its interim management statement for the quarter ended 31 March 2009. This constitutes the Company's first interim management statement for the financial year ending 31 December 2009, as required by Rule 4.3 of the Disclosure and Transparency Rules. A copy of this interim management statement can be found at www.yfmgroup.co.uk.

The unaudited net asset value per Ordinary share as at 31 March 2009 was 75.7p (31 December 2008: 76.9p). The net asset value as at 31 March 2009 is stated after taking account of the third interim dividend of 2.0p per Ordinary share in respect of the year ended 31 December 2008, which will be paid on 19 May 2009.

The total return at 31 March 2009, calculated by reference to the net asset value per share and the cumulative dividends paid and proposed, was 93.7p per share compared to 92.9p at 31 December 2008.

The number of Ordinary shares in issue at 31 March 2009 was 16,641,257. There were no shares purchased or issued by the Company during the quarter.

Net assets at 31 March 2009 comprised the following:

£000

% of net assets

Unquoted investments at fair value

6,493

51.5%

Quoted investment at bid price

1,178

9.4%

Gilt investments

4,313

34.2%

Total investments

11,984

95.1%

Cash and cash equivalents

634

5.0%

Other net current assets (liabilities)

(16)

(0.1%)

Net assets

12,602

100.0%

The ten largest investments by valuation at 31 March 2009 were as follows:

£000

% of net assets

Digital Healthcare Limited

2,112

16.8%

Silistix Limited

895 

7.1%

Immunobiology Limited

800 

6.3%

DxS Limited

792 

6.3%

Primal Pictures Limited

716 

5.7%

The ART Technology Group Inc

456 

3.6%

Pressure Technologies plc

350 

2.8%

Waterfall Services Limited

316 

2.5%

Ellfin Home Care Limited

312

2.4%

Harvey Jones Limited

247 

2.0%

Top ten investments

6,996

55.5%

Other investments

675

5.4%

Gilt investments

4,313

34.2%

Total investments

11,984

95.1%

Quoted investments are carried at bid price at 31 March 2009. Unquoted investment are carried at fair value as at 31 March 2009 as determined by the directors.

The movement in net asset value can be analysed as: 

Pence 

per share

NAV at 31.12.08

76.9

Less Dividend

(2.0) 

Change in underlying NAV

0.8

NAV at 31.03.09

75.7

The total return, calculated by reference to the net asset value plus cumulative dividend paid and proposed has increased by 0.8p to 93.7p, cumulative dividends representing 18 pence per share, the equivalent of 19.2%.

The net asset value currently comprises 39% in cash and gilts and as such the Company is well placed to take advantage of selective investment opportunities as they arise.

19 May 2009

For further information please contact:

David Hall YFM Private Equity Tel: 0161 832 7603

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSGUUCWAUPBGPB
Date   Source Headline
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:22 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:40 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
23rd Mar 202311:30 amRNSPublication of Circular
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNSAnnual Financial Report
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:50 amRNSTransaction in Own Shares
6th Dec 20229:58 amRNSOffer Update
6th Dec 20229:58 amRNSOffer Update
30th Nov 202212:30 pmRNSPublication of a Prospectus
30th Nov 202212:30 pmRNSPublication of a Prospectus
25th Nov 20229:30 amRNS3rd Quarter Results
4th Nov 20228:30 amRNSDividend Declaration
24th Oct 20229:00 amRNSChange of Registrar
3rd Oct 20221:30 pmRNSOffer Update
3rd Oct 20221:30 pmRNSOffer Update
3rd Oct 202212:24 pmRNSPayment of Dividend and Issue of Equity
28th Sep 202211:12 amRNSTransaction in Own Shares
20th Sep 20229:30 amRNSHalf-year Report
4th Aug 202211:45 amRNSDividend Declaration
2nd Aug 20221:15 pmRNSStatement re intention to fundraise
2nd Aug 20221:15 pmRNSStatement re intention to fundraise
29th Jun 202210:00 amRNSPurchase of Own Securities and Net Asset Value
21st Jun 20223:00 pmRNSInterim Management Statement
13th Jun 20223:51 pmRNSResult of AGM
6th May 20229:14 amRNSPayment of dividend and Issue of Equity
30th Mar 20228:00 amRNSTransaction in Own Shares
21st Mar 20221:15 pmRNSAnnual Financial Report
25th Feb 202212:03 pmRNSResult of General Meeting
31st Jan 202212:00 pmRNSPublication of Circular
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
7th Jan 202211:15 amRNSIssue of Equity and Close of Offers
16th Dec 20219:57 amRNSTransaction in Own Shares
6th Dec 202110:37 amRNSPublication of Supplementary Prospectus
6th Dec 202110:33 amRNSPublication of Supplementary Prospectus
18th Nov 20218:08 amRNSInterim Management Statement
16th Nov 202110:06 amRNSPayment of dividend and allotment of shares
12th Nov 20217:00 amRNSClose of Offers to New Applications
12th Nov 20217:00 amRNSClose of Offers to New Applications
25th Oct 202112:08 pmRNSPayment of Dividend and Issue of Equity
19th Oct 202110:14 amRNSNet Asset Value and Dividend Re-investment Scheme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.